You are here:

Mavenclad (cladribine) approved for Scotland

Published on

The Scottish Medicines Consortium (SMC) has approved Mavenclad (cladribine) as a treatment for highly active relapsing multiple sclerosis.

The SMC has recommended that Mavenclad can be prescribed by the NHS if you have:

  • rapidly evolving severe relapsing remitting MS: at least two relapses in the previous year and MRI evidence of MS activity
  • relapsing remitting MS that has responded inadequately to treatment with another disease modifying drug: at least one relapse in previous year and MRI evidence of MS activity

In November last year, NICE approved Mavenclad  for highly active relapsing MS in England and Wales.

About Mavenclad

Mavenclad is taken as a pill in two treatment courses, twelve months apart:

  • Year one – In the first course, Mavenclad pills are taken for four or five days consecutively at the beginning of the first month and then four or five days consecutively at the beginning of the second month.
  • Year two – The second course is taken 12 months later and follows the same pattern.

In clinical trials no further treatment was required in years three and four.

In clinical trials, Mavenclad reduced relapses by 58% compared to placebo and also reduced the risk of disability progression. Side effects included a reduced white blood cell count (lymphopenia) and herpes (shingles or cold sores).

Print this page